ONWARD MEDICAL BV EO -12 (63E) - Total Liabilities
Based on the latest financial reports, ONWARD MEDICAL BV EO -12 (63E) has total liabilities worth €29.24 Million EUR (≈ $34.18 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ONWARD MEDICAL BV EO -12 operating cash flow efficiency to assess how effectively this company generates cash.
ONWARD MEDICAL BV EO -12 - Total Liabilities Trend (2021–2025)
This chart illustrates how ONWARD MEDICAL BV EO -12's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of ONWARD MEDICAL BV EO -12 to evaluate the company's liquid asset resilience ratio.
ONWARD MEDICAL BV EO -12 Competitors by Total Liabilities
The table below lists competitors of ONWARD MEDICAL BV EO -12 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Starpharma Holdings Ltd
AU:SPL
|
Australia | AU$4.69 Million |
|
Spurcorp
JSE:SUR
|
South Africa | ZAC608.93 Million |
|
MPC Münchmeyer Petersen Capital AG
F:MPCK
|
Germany | €21.91 Million |
|
Virgin Galactic Holdings Inc
NYSE:SPCE
|
USA | $627.65 Million |
|
Newbury Street II Acquisition Corp Class A Ordinary Shares
NASDAQ:NTWO
|
USA | $6.18 Million |
|
Tele2 AB (publ)
ST:TEL2-A
|
Sweden | Skr41.14 Billion |
|
Vakif Finansal Kiralama AS
IS:VAKFN
|
Turkey | TL28.82 Billion |
|
Graphite One Inc
V:GPH
|
Canada | CA$3.66 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ONWARD MEDICAL BV EO -12's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of ONWARD MEDICAL BV EO -12.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ONWARD MEDICAL BV EO -12's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ONWARD MEDICAL BV EO -12 (2021–2025)
The table below shows the annual total liabilities of ONWARD MEDICAL BV EO -12 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €29.24 Million ≈ $34.18 Million |
+4.11% |
| 2024-12-31 | €28.08 Million ≈ $32.83 Million |
+9.28% |
| 2023-12-31 | €25.70 Million ≈ $30.04 Million |
+7.24% |
| 2022-12-31 | €23.96 Million ≈ $28.01 Million |
+8.36% |
| 2021-12-31 | €22.11 Million ≈ $25.85 Million |
-- |
About ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more